The study aim to assess demographic and clinical characteristics , treatment patterns and as exploratory analysis will descriptively assess the time to clinical events of NVAF patients treated with oral anticoagulants (OACs) in Colombia through observational, descriptive study of a retrospective cohort of adult patients diagnosed with NVAF in selected Health Maintenance Organizations (HMO) of Colombia. The information will be used in the study comes exclusively form secondary sources: claim databases and medical records.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Time to Diagnose NVAF by Each OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
Number of Participants With Comorbidities
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants With Uncontrolled Hypertension at OAC Prescription Date
Timeframe: At index date (any time between 01-January-2013 to 30-June-2018)
Number of Participants With Use of Aspirin at Start OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
Number of Participants With Use of Clopidogrel at Start of OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
Number of Participants With Use of Non-Steroidal Anti-Inflammatory Drugs at Start of OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
HAS-BLED Score at Start of OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
CHA2DS2-VASc Score at Start of OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
Number of Participants With Anemia at Start of OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
Number of Participants With Stroke
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Duration of Follow-up in Participants With Stroke
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants According to Type of Stroke
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants With Pulmonary Embolism
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Duration of Follow-up in Participants With Pulmonary Embolism
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants With Gastrointestinal Bleeding
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Duration of Follow-up in Participants With Gastrointestinal Bleeding
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants With Intracranial Bleeding
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Duration of Follow-up in Participants With Intracranial Bleeding
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Deaths
Timeframe: From index date until death or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Duration of Follow-up in Participants Who Died
Timeframe: From index date until death or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Time Under OAC Treatment (Persistence) by Each OAC Treatment
Timeframe: From index date until switch of treatment, discontinuation, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants With Other Major Bleeding
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Duration of Follow-up in Participants With Other Major Bleeding
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Dose of Initial OAC Prescription by Each OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
Number of Doses Dispensed at Initial OAC Treatment by Each OAC Treatment
Timeframe: At index date (anytime between 01-January-2013 to 30-June-2018)
Number of Participants With Dose Reduction by Each OAC Treatment
Timeframe: From baseline (index date) until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Time to Dose Reduction by Each OAC Treatment
Timeframe: From index date until date of dose reduction or until end of follow-up, anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants With Treatment Discontinuation
Timeframe: From index date until date of discontinuation, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Time to Discontinuation
Timeframe: From index date until date of discontinuation, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants According to Reasons for Discontinuation
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants According to INR Measurements During Follow-up (Warfarin Group Only)
Timeframe: From 1 Month to maximum 6.5 years (Jan 2013 to Jul 2019)
Number of Participants Who Switched to Another OAC Treatment
Timeframe: From index date until switch of treatment or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Time to Switch to Another OAC Treatment
Timeframe: From index date until switch of treatment or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants According to Reasons for Switching OAC Treatment
Timeframe: From index date until switch of treatment, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants With Concomitant Therapies by OAC Prescription
Timeframe: From index date until switch of treatment, discontinuation, death, first stroke/systemic embolism, or major bleeding, or until end of follow-up, whichever occurred first anytime between Jan 2013 to Jul 2019(approximately 6.5 years)
Number of Participants Who Were Previously Exposed to Warfarin (NOACs Group Only)
Timeframe: Up to 6 months prior to index date